[시장보고서]아시아태평양의 사코페니아 치료 시장 전망(-2030년) : 지역별 분석

아시아태평양의 사코페니아 치료 시장 전망(-2030년) : 지역별 분석 - 치료 유형별, 유통 채널별, 지역별 분석

Asia Pacific Sarcopenia Treatment Market Forecast to 2030 - Regional Analysis - by Treatment Type and Distribution Channel

상품코드 : 1562380 해당 상품은 즉시 배송 가능합니다

리서치사 : The Insight Partners

발행일 : 2024년 07월

페이지 정보 : 영문 78 Pages

라이선스 & 가격 (부가세 별도)

US $ 3,450

￦ 4,819,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다.

US $ 4,450

￦ 6,216,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 5,450

￦ 7,613,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

아시아태평양의 사코페니아 치료 시장은 2022년 6억 9,685만 달러로 평가되었습니다. 2030년에는 11억 6,404만 달러에 달할 것으로 예상되며, 2022-2030년간 연평균 6.6%의 성장률을 나타낼 것으로 예상됩니다.

임상시험 단계의 제품이 아시아태평양의 사코페니아 치료제 시장을 주도하고 있습니다.

근감소증 치료 시장에 진출한 여러 대기업들이 근감소증 치료제 개발에 점점 더 많은 노력을 기울이고 있습니다. 현재 새로운 사코페니아 치료제가 개발되어 임상시험이 진행되고 있습니다.

따라서 임상 개발 단계에 있는 다양한 약품 파이프라인의 출현은 사코페니아 치료제 시장의 성장에 큰 기회가 될 것입니다.

아시아태평양의 사코페니아 치료제 시장 개요

아시아태평양의 사코페니아 치료 시장은 중국, 인도, 일본, 한국, 호주, 기타 아시아태평양으로 구분됩니다. 아시아태평양은 예측 기간 동안 세계 시장에서 가장 빠른 CAGR을 나타낼 것으로 예상됩니다. 아시아는 세계에서 가장 인구가 많고 빠르게 고령화되는 대륙이며, 아시아 여러 국가에서 근육 감소증과 관련된 문제가 만연하고 있습니다. 아시아인의 라이프스타일은 서양인과 크게 다르며 식습관도 다릅니다. 아시아에서는 남성(9.6-22.1%)이 여성(7.7-21.8%)보다 남성(9.6-22.1%)에게서 더 많이 발생하며, 아시아 근감소증 워킹그룹(Asian Working Group for Sarcopenia, AWGS)은 아시아에서 근감소증 연구를 촉진하는 것을 목표로 하고 있습니다.

아시아태평양의 사코페니아 치료제 시장 매출 및 2030년까지 예측(금액)

아시아태평양의 사코페니아 치료제 시장 세분화

아시아태평양 근육 감소증 치료 시장은 치료 유형, 유통 채널 및 국가별로 분류됩니다.

치료 유형별로는 비타민D 및 칼슘 보충제, 단백질 보충제, 비타민 B12 보충제, 기타로 구분되며, 2022년 아시아태평양의 사코페니아 치료 시장은 비타민D 및 칼슘 보충제 부문이 가장 큰 시장 점유율을 차지할 것으로 예상됩니다. 칼슘 보충제 부문이 가장 큰 시장 점유율을 차지할 것으로 예상됩니다.

유통 채널에 따라 아시아태평양의 근육 감소증 치료 시장은 약국, 소매 채널, 온라인 채널 및 기타로 구분되며, 2022년 아시아태평양의 근육 감소증 치료 시장 점유율은 약국 부문이 가장 큰 것으로 나타났습니다.

국가별로는 아시아태평양의 근육 감소증 치료 시장은 중국, 인도, 일본, 호주, 한국, 기타 아시아태평양으로 구분되며, 2022년 아시아태평양의 근육 감소증 치료 시장 점유율은 중국이 독점할 것으로 예상됩니다.

Abbott Laboratories, Bayer AG, Metagenics LLC, Nestle Health Science SA, Novartis AG, Pfizer Inc, Sanofi SA, Amway Corp, GSK Plc는 아시아태평양의 사코페니아 치료제 시장에서 사업을 운영하는 주요 기업 중 일부입니다.

영문목차

The Asia Pacific sarcopenia treatment market was valued at US$ 696.85 million in 2022 and is expected to reach US$ 1,164.04 million by 2030; it is estimated to register a CAGR of 6.6% from 2022 to 2030.

Products in Clinical Trial Phases Drive Asia Pacific Sarcopenia Treatment Market

A few major players operating in the sarcopenia treatment market are increasingly focusing on drug development to treat sarcopenia. Novel sarcopenia treatments are currently being developed and tested in clinical trials. A few of these products are mentioned below:

Table 1. Sarcopenia Drug Under Clinical Development

Company Name Interventions Conditions Clinical Trial Stage

Abbott Nutrition Medical Food with AN777

Oral Nutritional Formula Malnutrition

Sarcopenia PHASE3

Nutricia Research Dietary Supplement: Bolus ONS A

Dietary Supplement: Bolus ONS B

Dietary Supplement: Bolus ONS C

Dietary Supplement: Bolus ONS D Sarcopenia PHASE1

Novartis Pharmaceuticals Drug: Bimagrumab Sarcopenia PHASE2

McMaster University Behavioural: Step Reduction Sarcopenia PHASE1

Metabolic Technologies Inc. Dietary Supplement: Placebo

Drug: HMB Plus Vitamin D

Behavioural: Non-Exercise

Behavioural: Exercise Sarcopenia PHASE1

Merck Sharp & Dohme LLC Drug: Comparator MK-077

Drug: Comparator Placebo Sarcopenia PHASE2

Immunotec Inc. Dietary Supplement: Immunocal

Dietary Supplement: Casein Aging and Sarcopenia PHASE2

Lijun Yang Combination Product: 3-Month Intensive Intervention Sarcopenia PHASE4

Regeneron Pharmaceuticals Drug: REGN1033 (SAR391786)

Drug: Placebo Sarcopenia PHASE2

Source: Company Websites and The Insight Partners Analysis

Therefore, the extending pipeline of drugs that are in different stages of clinical development presents significant opportunities for the sarcopenia treatment market growth.

Asia Pacific Sarcopenia Treatment Market Overview

The Asia Pacific sarcopenia treatment market is segmented into China, India, Japan, South Korea, Australia, and the Rest of Asia Pacific. Asia Pacific is expected to register the fastest CAGR in the global market during the forecast period. Asia is the world's most populated continent with a rapidly aging population, and sarcopenia-related issues are becoming more prevalent in several Asian countries. Asians led extremely different lifestyles and follow different dietary habits than people from the Western world. In Asia, sarcopenia in older individuals is more common in males (prevalence 9.6-22.1%) than females (prevalence 7.7-21.8%). Asian Working Group for Sarcopenia (AWGS) aims to promote sarcopenia research in Asia.

Asia Pacific Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Million)

Asia Pacific Sarcopenia Treatment Market Segmentation

The Asia Pacific sarcopenia treatment market is categorized into treatment type, distribution channel, and country.

Based on treatment type, the Asia Pacific sarcopenia treatment market is segmented into vitamin D and calcium supplement, protein supplement, vitamin B12 supplement, and others. The vitamin D and calcium supplement segment held the largest Asia Pacific sarcopenia treatment market share in 2022.

In terms of distribution channel, the Asia Pacific sarcopenia treatment market is segmented into pharmacies, retail channels, online channels, and others. The pharmacies segment held the largest Asia Pacific sarcopenia treatment market share in 2022.

By country, the Asia Pacific sarcopenia treatment market is segmented into China, India, Japan, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific sarcopenia treatment market share in 2022.

Abbott Laboratories, Bayer AG, Metagenics LLC, Nestle Health Science SA, Novartis AG, Pfizer Inc, Sanofi SA, Amway Corp, and GSK Plc are some of the leading companies operating in the Asia Pacific sarcopenia treatment market.

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Asia Pacific Sarcopenia Treatment Market - Key Industry Dynamics

4.1 Asia Pacific Sarcopenia Treatment Market - Key Industry Dynamics
4.2 Market Drivers
- 4.2.1 Upsurge in Geriatric Population
- 4.2.2 Rise in Malnutrition and Vitamin Deficiency Among Adults
4.3 Key Market Restraints:
- 4.3.1 Unavailability of Direct Interventions
4.4 Key Market Opportunities:
- 4.4.1 Products in Clinical Trial Phases
4.5 Future Trends:
- 4.5.1 Rising Awareness About Sarcopenia
4.6 Impact of Drivers and Restraints:

5. Sarcopenia Treatment Market - Asia Pacific Market Analysis

5.1 Asia Pacific Sarcopenia Treatment Market Revenue (US$ Million), 2020 - 2030
5.2 Asia Pacific Sarcopenia Treatment Market Forecast and Analysis

6. Asia Pacific Sarcopenia Treatment Market Analysis - By Treatment Type

6.1 Vitamin D and Calcium Supplement
- 6.1.1 Overview
- 6.1.2 Vitamin D and Calcium Supplement: Asia Pacific Sarcopenia Treatment Market, Revenue and Forecast to 2030 (US$ Million)
6.2 Protein Supplement
- 6.2.1 Overview
- 6.2.2 Protein Supplement : Asia Pacific Sarcopenia Treatment Market, Revenue and Forecast to 2030 (US$ Million)
6.3 Vitamin B12 Supplement
- 6.3.1 Overview
- 6.3.2 Vitamin B12 Supplement: Asia Pacific Sarcopenia Treatment Market, Revenue and Forecast to 2030 (US$ Million)
6.4 Others
- 6.4.1 Overview
- 6.4.2 Others : Asia Pacific Sarcopenia Treatment Market, Revenue and Forecast to 2030 (US$ Million)

7. Asia Pacific Sarcopenia Treatment Market Analysis - By Distribution Channel

7.1 Pharmacies
- 7.1.1 Overview
- 7.1.2 Pharmacies : Asia Pacific Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Million)
7.2 Retail Channels
- 7.2.1 Overview
- 7.2.2 Retail Channels : Asia Pacific Sarcopenia Treatment Market, Revenue and Forecast to 2030 (US$ Million)
7.3 Online Channels
- 7.3.1 Overview
- 7.3.2 Online Channels : Asia Pacific Sarcopenia Treatment Market, Revenue and Forecast to 2030 (US$ Million)
7.4 Others
- 7.4.1 Overview
- 7.4.2 Others : Asia Pacific Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Million)

8. Asia Pacific Sarcopenia Treatment Market - Country Analysis

8.1 Asia Pacific
- 8.1.1 Asia Pacific Sarcopenia Treatment Market Revenue and Forecast and Analysis - By Country
  - 8.1.1.1 Asia Pacific Sarcopenia Treatment Market Revenue and Forecast and Analysis - By Country
  - 8.1.1.2 China Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Mn)
    - 8.1.1.2.1 China Sarcopenia Treatment Market Breakdown by Treatment Type
    - 8.1.1.2.2 China Sarcopenia Treatment Market Breakdown by Distribution Channel
  - 8.1.1.3 India Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Mn)
    - 8.1.1.3.1 India Sarcopenia Treatment Market Breakdown by Treatment Type
    - 8.1.1.3.2 India Sarcopenia Treatment Market Breakdown by Distribution Channel
  - 8.1.1.4 Japan Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Mn)
    - 8.1.1.4.1 Japan Sarcopenia Treatment Market Breakdown by Treatment Type
    - 8.1.1.4.2 Japan Sarcopenia Treatment Market Breakdown by Distribution Channel
  - 8.1.1.5 South Korea Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Mn)
    - 8.1.1.5.1 South Korea Sarcopenia Treatment Market Breakdown by Treatment Type
    - 8.1.1.5.2 South Korea Sarcopenia Treatment Market Breakdown by Distribution Channel
  - 8.1.1.6 Australia Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Mn)
    - 8.1.1.6.1 Australia Sarcopenia Treatment Market Breakdown by Treatment Type
    - 8.1.1.6.2 Australia Sarcopenia Treatment Market Breakdown by Distribution Channel
  - 8.1.1.7 Rest of Asia Pacific Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Mn)
    - 8.1.1.7.1 Rest of Asia Pacific Sarcopenia Treatment Market Breakdown by Treatment Type
    - 8.1.1.7.2 Rest of Asia Pacific Sarcopenia Treatment Market Breakdown by Distribution Channel

9. Sarcopenia Treatment Market-Industry Landscape

9.1 Overview
9.2 Growth Strategies in the Sarcopenia Treatment Market
9.3 Inorganic Growth Strategies
- 9.3.1 Overview
9.4 Organic Growth Strategies
- 9.4.1 Overview

10. Company Profiles

10.1 Abbott Laboratories
- 10.1.1 Key Facts
- 10.1.2 Business Description
- 10.1.3 Products and Services
- 10.1.4 Financial Overview
- 10.1.5 SWOT Analysis
- 10.1.6 Key Developments
10.2 Bayer AG
- 10.2.1 Key Facts
- 10.2.2 Business Description
- 10.2.3 Products and Services
- 10.2.4 Financial Overview
- 10.2.5 SWOT Analysis
- 10.2.6 Key Developments
10.3 Metagenics LLC
- 10.3.1 Key Facts
- 10.3.2 Business Description
- 10.3.3 Products and Services
- 10.3.4 Financial Overview
- 10.3.5 SWOT Analysis
- 10.3.6 Key Developments
10.4 Nestle Health Science SA
- 10.4.1 Key Facts
- 10.4.2 Business Description
- 10.4.3 Products and Services
- 10.4.4 Financial Overview
- 10.4.5 SWOT Analysis
- 10.4.6 Key Developments
10.5 Novartis AG
- 10.5.1 Key Facts
- 10.5.2 Business Description
- 10.5.3 Products and Services
- 10.5.4 Financial Overview
- 10.5.5 SWOT Analysis
- 10.5.6 Key Developments
10.6 Pfizer Inc
- 10.6.1 Key Facts
- 10.6.2 Business Description
- 10.6.3 Products and Services
- 10.6.4 Financial Overview
- 10.6.5 SWOT Analysis
- 10.6.6 Key Developments
10.7 Sanofi SA
- 10.7.1 Key Facts
- 10.7.2 Business Description
- 10.7.3 Products and Services
- 10.7.4 Financial Overview
- 10.7.5 SWOT Analysis
- 10.7.6 Key Developments
10.8 Amway Corp
- 10.8.1 Key Facts
- 10.8.2 Business Description
- 10.8.3 Products and Services
- 10.8.4 Financial Overview
- 10.8.5 SWOT Analysis
- 10.8.6 Key Developments
10.9 GSK Plc
- 10.9.1 Key Facts
- 10.9.2 Business Description
- 10.9.3 Products and Services
- 10.9.4 Financial Overview
- 10.9.5 SWOT Analysis
- 10.9.6 Key Developments

11. Appendix

11.1 About The Insight Partners
11.2 Glossary of Terms

한글목차

목차

제1장 서론

제2장 주요 요약

제3장 조사 방법

제4장 아시아태평양의 사코페니아 치료 시장 - 주요 산업 역학

제5장 사코페니아 치료 시장 : 아시아태평양 시장 분석

제6장 아시아태평양의 사코페니아 치료 시장 분석 - 치료 유형별

제7장 아시아태평양의 사코페니아 치료 시장 분석 - 유통 채널별

제8장 아시아태평양의 사코페니아 치료 시장 : 국가별 분석

제9장 사코페니아 치료 시장 - 업계 상황

제10장 기업 개요

제11장 부록